MWNA
AMAM

Marshall Wace North America’s Ambrx Biopharma Inc AMAM Stock Holding History

Marshall Wace North America’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-32,648
Closed -$640K – 1795
2021
Q2 		$640K Buy
+32,648
New +$556K ﹤0.01% 1115

Other funds holding AMAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Marshall Wace North America's AMAM Position: Q3 2021 in Review

Marshall Wace North America sold out of Ambrx Biopharma Inc (AMAM) in Q3 2021, closing a stake of 32,648 shares — an estimated $640K sold.

Marshall Wace North America first reported a position in AMAM in Q2 2021 and held it in 1 quarter. The position peaked at $640K in Q2 2021. 15 funds tracked by Wall St. Rank hold AMAM as of Q3 2021.

  • Marshall Wace North America reported no remaining Ambrx Biopharma Inc position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 32,648 Ambrx Biopharma Inc shares in Q3 2021, an estimated $640K.
  • Marshall Wace North America first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Ambrx Biopharma Inc position peaked at $640K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.